Outlook Therapeutics, Inc.
OTLK · XNASCIK 1649989fmd_1J9RJQW3S8SW7STQZSDCTM8YMG制造业 · 生物制品（不含诊断试剂）模板: 标准
覆盖范围: 2014年10月01日 至 2026年6月30日，共 46 个期间
| 项目 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 营业总收入 | 3 | 4 | 3 | 8 | – | – | – | – | – | 1 |
| 净利息收入 | – | – | – | – | (2) | (1) | (1) | (2) | (3) | (0) |
| 营业成本 | – | – | – | – | – | – | – | – | – | 1 |
| 毛利润 | – | – | – | – | – | – | – | – | – | 0 |
| 研发费用 | 33 | 24 | 19 | 24 | 26 | 39 | 42 | 26 | 42 | 27 |
| 销售、一般及管理费用 | – | – | – | – | – | – | – | – | 30 | 40 |
| 营业费用合计 | 54 | 40 | 33 | 44 | 37 | 52 | – | – | – | – |
| 营业利润 | (51) | (36) | (30) | (36) | (37) | (52) | (63) | (53) | (72) | (67) |
| 利息费用 | 2 | 6 | 4 | 3 | 2 | – | – | 3 | 3 | – |
| 利息及投资收益 | – | – | – | – | – | – | – | 1 | 1 | 0 |
| 税前利润 | (53) | (38) | (34) | (38) | (39) | (53) | (66) | (59) | (75) | (64) |
| 所得税费用 | 0 | 1 | (4) | (3) | (3) | 0 | 0 | 0 | 0 | (2) |
| 持续经营净利润 | (53) | (39) | (30) | (35) | (35) | (53) | (66) | (59) | (75) | (62) |
| 净利润 | (53) | (39) | (30) | (35) | (35) | (53) | (66) | (59) | (75) | (62) |
| 归属于普通股股东的净利润 | (63) | (40) | (48) | (36) | (49) | (53) | (66) | (59) | (75) | (62) |